Peel Hunt reaffirmed their hold rating on shares of Vectura Group (LON:VEC) in a research note published on Thursday, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts have also recently issued reports on VEC. JPMorgan Chase & Co. cut their target price on Vectura Group from GBX 140 ($1.83) to GBX 110 ($1.44) and set an overweight rating on the stock in a research note on Wednesday, January 2nd. Shore Capital reiterated a hold rating on shares of Vectura Group in a research note on Thursday, January 3rd. Finally, Numis Securities initiated coverage on Vectura Group in a research note on Thursday, January 3rd. They issued a buy rating and a GBX 160 ($2.09) target price on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Vectura Group presently has a consensus rating of Buy and a consensus price target of GBX 114.33 ($1.49).
VEC traded up GBX 0.15 ($0.00) during trading hours on Thursday, hitting GBX 72.35 ($0.95). 177,109 shares of the stock were exchanged, compared to its average volume of 4,610,000. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.35 and a quick ratio of 1.90. The stock has a market capitalization of $480.18 million and a PE ratio of -5.48. Vectura Group has a 12 month low of GBX 65.85 ($0.86) and a 12 month high of GBX 90.15 ($1.18).
About Vectura Group
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Read More: Certificate of Deposit (CD)
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.